Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) Operating Income (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Operating Income data on record, last reported at -$18.3 million in Q4 2025.

  • For Q4 2025, Operating Income rose 9.91% year-over-year to -$18.3 million; the TTM value through Dec 2025 reached -$76.9 million, down 36.76%, while the annual FY2025 figure was -$76.9 million, 36.76% down from the prior year.
  • Operating Income reached -$18.3 million in Q4 2025 per PLSE's latest filing, up from -$20.4 million in the prior quarter.
  • Across five years, Operating Income topped out at -$8.7 million in Q4 2022 and bottomed at -$20.4 million in Q3 2025.
  • Average Operating Income over 5 years is -$14.9 million, with a median of -$14.5 million recorded in 2021.
  • Peak YoY movement for Operating Income: surged 44.64% in 2023, then plummeted 72.91% in 2025.
  • A 5-year view of Operating Income shows it stood at -$15.4 million in 2021, then soared by 43.25% to -$8.7 million in 2022, then plummeted by 43.32% to -$12.5 million in 2023, then tumbled by 61.66% to -$20.3 million in 2024, then increased by 9.91% to -$18.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$18.3 million in Q4 2025, -$20.4 million in Q3 2025, and -$20.3 million in Q2 2025.